Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) BCR-ABL1 chimeric transcripts

IF 1.9 Q2 MEDICINE, GENERAL & INTERNAL Precision and Future Medicine Pub Date : 2019-03-31 DOI:10.23838/PFM.2019.00023
J. Yun, Jung Yoon, Jong-Won Kim, Sun-Hee Kim, C. Jung, Hee-Jin Kim
{"title":"Isolated monocytosis was the flag preceding abnormalities in other parameters of complete blood counts in chronic myeloid leukemia with e1a2 (minor, P190) BCR-ABL1 chimeric transcripts","authors":"J. Yun, Jung Yoon, Jong-Won Kim, Sun-Hee Kim, C. Jung, Hee-Jin Kim","doi":"10.23838/PFM.2019.00023","DOIUrl":null,"url":null,"abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most commonly producing the e14a2 or e13a2 type. CML with e1a2 BCR-ABL1 by fusion in minor bcr is rare, accounting for approximately 1% of CML. CML with e1a2 BCR-ABL1 is reportedly associated with monocytosis and poor prognosis. Here we describe a woman who underwent bone marrow (BM) study with an impression of chronic myelomonocytic leukemia based on thrombocytosis and prominent monocytosis. Genetic workup revealed, however, t(9;22) and e1a2 BCR-ABL1, which indicated CML and explained her unusual monocytosis. A review of serial complete blood counts (CBC) before the BM study demonstrated that isolated monocytosis preceded the abnormalities in other parameters of CBC. The patient is on follow-up with tyrosine kinase inhibitor (TKI, dasatinib) medication. Close monitoring is required due to the association of e1a2 BCR-ABL1 with poor response to TKI and frequent disease progression. Timely genetic workup and determination of the precise type of BCR-ABL1 transcripts are critical for the diagnosis and stratification of this rare subtype of CML with distinct genotype-phenotype correlations.","PeriodicalId":42462,"journal":{"name":"Precision and Future Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2019-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Precision and Future Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23838/PFM.2019.00023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 1

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with the molecular hallmark of BCR-ABL1 chimeric transcripts from t(9;22)(q24;q22). In more than 95% of CML, the fusion occurs in the major breakpoint cluster region (M-bcr) of BCR, most commonly producing the e14a2 or e13a2 type. CML with e1a2 BCR-ABL1 by fusion in minor bcr is rare, accounting for approximately 1% of CML. CML with e1a2 BCR-ABL1 is reportedly associated with monocytosis and poor prognosis. Here we describe a woman who underwent bone marrow (BM) study with an impression of chronic myelomonocytic leukemia based on thrombocytosis and prominent monocytosis. Genetic workup revealed, however, t(9;22) and e1a2 BCR-ABL1, which indicated CML and explained her unusual monocytosis. A review of serial complete blood counts (CBC) before the BM study demonstrated that isolated monocytosis preceded the abnormalities in other parameters of CBC. The patient is on follow-up with tyrosine kinase inhibitor (TKI, dasatinib) medication. Close monitoring is required due to the association of e1a2 BCR-ABL1 with poor response to TKI and frequent disease progression. Timely genetic workup and determination of the precise type of BCR-ABL1 transcripts are critical for the diagnosis and stratification of this rare subtype of CML with distinct genotype-phenotype correlations.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分离单核细胞增多症是e1a2 (minor, P190) BCR-ABL1嵌合转录物慢性髓系白血病全血细胞计数其他参数异常的标志
慢性粒细胞白血病(CML)是一种骨髓增生性肿瘤,具有来自t(9;22)(q24;q22)的BCR-ABL1嵌合转录物的分子标志。在95%以上的CML中,融合发生在bcr的主要断点簇区(M-bcr),最常见的是产生e14a2或e13a2型。在小BCR中融合e1a2 BCR-ABL1的CML是罕见的,约占CML的1%。据报道,患有e1a2 BCR-ABL1的CML与单核细胞增多症和预后不良有关。在这里,我们描述了一位接受骨髓(BM)研究的女性,她有一种基于血小板增多症和显著单核细胞增多症的慢性粒单核细胞白血病的印象。然而,基因检查显示t(9;22)和e1a2 BCR-ABL1,这表明CML,并解释了她不寻常的单核细胞增多症。BM研究前对系列全血细胞计数(CBC)的回顾表明,孤立的单核细胞增多症先于CBC的其他参数异常。患者正在接受酪氨酸激酶抑制剂(TKI,达沙替尼)药物的随访。由于e1a2 BCR-ABL1与TKI反应差和疾病进展频繁有关,需要密切监测。及时的基因检查和BCR-ABL1转录物精确类型的确定对于诊断和分层这种具有不同基因型-表型相关性的罕见CML亚型至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Precision and Future Medicine
Precision and Future Medicine MEDICINE, GENERAL & INTERNAL-
自引率
0.00%
发文量
15
审稿时长
10 weeks
期刊最新文献
Survival rate and death risk for associated pulmonary arterial hypertension: A retrospective population-based study Understanding hikikomori syndrome in clinical settings: a case series Development of colistin resistance via heteroresistance modeling in Klebsiella pneumoniae: A diagnostic study Paraneoplastic neurological syndrome associated with onconeural autoantibodies: report of two cases Durable response to first-line treatment with AZD3759 (zorifertinib) in a patient with epithelial growth factor receptor mutated non-small cell lung cancer and untreated multiple brain metastasis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1